A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Status:
Not yet recruiting
Trial end date:
2025-05-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine clinical advantages for LP-300 in combination with
carboplatin and pemetrexed in the never smoker patient population. The primary objectives of
this study are to determine progression-free survival (PFS) and overall survival (OS) in the
study-defined patient population when LP-300 is co-administered with the standard of care
chemotherapy drugs carboplatin and pemetrexed compared to carboplatin and pemetrexed alone.
This has been designed as a multicenter, open label, phase II trial with 90 patients to be
enrolled in the United States.